Predictors of the Overall Survival with Azacitidine Monotherapy in Untreated Acute Myeloid Leukemia Patients Ineligible for Intensive Therapy

Objective The prognostic factors for azacitidine in untreated acute myeloid leukemia (AML) patients ineligible for intensive therapy remain unknown. To identify prognostic factors for azacitidine monotherapy and assist clinicians in deciding whether to use azacitidine monotherapy or other therapies....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Internal Medicine 2023/03/01, Vol.62(5), pp.689-695
Hauptverfasser:	Taenaka, Ryutaro, Obara, Teppei, Kohno, Kentaro, Aoki, Kenichi, Ogawa, Ryosuke
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Antineoplastic Combined Chemotherapy Protocols - therapeutic use azacitidine Azacitidine - therapeutic use Humans Internal medicine Leukemia Leukemia, Myeloid, Acute Medical prognosis Multivariate analysis Original overall survival Patients prognostic factors Retrospective Studies Survival Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objective The prognostic factors for azacitidine in untreated acute myeloid leukemia (AML) patients ineligible for intensive therapy remain unknown. To identify prognostic factors for azacitidine monotherapy and assist clinicians in deciding whether to use azacitidine monotherapy or other therapies. Methods We retrospectively analyzed 27 patients with AML who were newly treated with azacitidine between 2013 and 2021 at our hospital. We evaluated potential predictors based on the overall survival (OS). Results A univariate analysis found that an Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2 and platelet count (Plt)
ISSN:	0918-2918 1349-7235
DOI:	10.2169/internalmedicine.0264-22